2-甲基戊-4-炔酸 | 74064-82-7

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 中文名称: 2-甲基戊-4-炔酸
• 英文名称: 2-methylpent-4-ynoic acid
• CAS: 74064-82-7
• 化学式: C₆H₈O₂
• mdl: MFCD19228215
• 分子量: 112.128
• InChiKey: MUIUIMCXQOKXTL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  8
• 可旋转键数：
  2
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-甲基戊-4-炔酸 在 1,4-二氧六环 、 lithium aluminium tetrahydride 、 草酸氯化物 、 硫酸 、 sodium hydride 、 N,N-二甲基甲酰胺 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 47.0h， 生成 (2R)-benzyl-(2-methylpent-4-ynyl) ether
  参考文献：
  名称：

  (??)-xyloketal D 及其对映异构体的全合成 ?? 绝对立体化学的确认

  摘要：

  (??)-xyloketal D 及其对映体的全合成是通过邻醌甲基化物与 (4R)- 和 (4S)-4,5-二氢-2,4-二甲基呋喃通过非对映选择性反应实现的逆电子需求 Diels??Alder 反应。这种全合成证实了天然产物的绝对立体化学。通过适当官能化的曼尼希碱与甲基碘反应生成邻醌甲基化物。曼尼希碱由 2,4-二羟基苯乙酮、甲醛和吗啉一步制备而成。对映体二氢呋喃由 (2R)- 和 (2S)-2-methylpent-4-ynoic 酸通过三步反应序列制备。这些手性非外消旋合成前体是从相应的 (R)-苯基甘氨醇衍生的非对映异构酰胺容易获得的外消旋羧酸制备的。

  DOI：

  10.1139/v04-138
• 作为产物：
  描述：

  alkaline earth salt of/the/ methylsulfuric acid 生成 2-甲基戊-4-炔酸
  参考文献：
  名称：

  Perkin; Simonsen, Journal of the Chemical Society, 1907, vol. 91, p. 832

  摘要：

  DOI：

文献信息

• Smaller, faster, better: modular synthesis of unsymmetrical ammonium salt-tagged NHC–gold(<scp>i</scp>) complexes and their application as recyclable catalysts in water
  作者：Katrin Belger、Norbert Krause

  DOI：10.1039/c5ob01286d

  日期：——

  Facile access towards a small library of unsymmetrical ammonium salt-tagged N-heterocyclic carbene gold(I) complexes is described, and their application as recyclable catalysts in cyclization reactions of acetylenic carboxylic acids and amides to lactones and lactams, respectively, in aqueous media is demonstrated. Catalyst 1ab was applied in the synthesis of 2-epi-clausemarine A (16).

  可以方便地访问不对称铵盐标记的N-杂环卡宾金（I）络合物的小型文库，并且将其作为可循环催化剂用于水性介质中炔属羧酸和酰胺分别环化为内酯和内酰胺的可循环催化剂。演示。催化剂1ab用于2- epi- clausemarine A（16）的合成。
• 5,11-dihydro-6H-pyrido(2,3-B)(1,4)benzodiazepin-6-ones substituted in
  申请人：Karl Thomae GmbH

  公开号：US04724236A1

  公开（公告）日：1988-02-09

  Compounds of general formula I are described, ##STR1## wherein X represents the group .dbd.CHR, .dbd.NR or an oxygen atom and A represents the groups --NR.sup.1 R.sup.2, wherein R.sup.1 and R.sup.2 represent alkyl, cycloalkyl or phenylalkyl groups, n represents the number 0, 1 or 2, R.sup.3 represents a hydrogen atom, a hydroxy or alkyl group or a group --(CH.sub.2).sub.n --N--R.sup.5 R.sup.6 (R.sup.5 and R.sup.6 being lower alkyl groups) and R.sup.4 is an alkyl or phenylalkyl group; two processes for preparing these compounds and the salts thereof are also described. The compounds have favourable effects on heart rate and can be used as vagal pacemakers for treating bradycardia and bradyarrhythmia in human and veterinary medicine. Some of these compounds also have very good antithrombotic effects.

  通式I的化合物描述如下，其中X代表基团.dbd.CHR，.dbd.NR或氧原子，A代表基团--NR.sup.1 R.sup.2，其中R.sup.1和R.sup.2代表烷基、环烷基或苯基烷基基团，n代表数字0、1或2，R.sup.3代表氢原子、羟基或烷基基团或基团--(CH.sub.2).sub.n --N--R.sup.5 R.sup.6（R.sup.5和R.sup.6为较低的烷基基团），R.sup.4是烷基或苯基烷基基团；还描述了制备这些化合物及其盐的两种方法。这些化合物对心率有良好的影响，并可用作治疗人类和兽医学中的心动过缓和心动过缓性心律失常的迷走神经起搏器。其中一些化合物还具有非常好的抗血栓作用。
• Method for producing anellated tetrahydro-{1h}-triazoles
  申请人：——

  公开号：US20040097728A1

  公开（公告）日：2004-05-20

  The present invention relates to a process for preparing fused tetrahydro-[ 1 H]-triazoles of the formula I 1 where the variables R a , Z, Z 1 , X, W, n and Q are as defined in claim 1, by cyclization of compounds of the formula II 2 where R is C(X)OR 2 or C(X)SR 2 , where X is oxygen or sulfur, and R 2 is as defined in claim 1, in the presence of a base. The invention also relates to compounds of the formula I where W is sulfur if Z is a methylene group optionally substituted by R a , and furthermore to compounds of the formula I where Q is a benzoxazole or benzothiazole radical, and to the use of these compounds as herbicides.

  本发明涉及一种制备公式I的熔融四氢咪唑的方法，其中变量Ra、Z、Z1、X、W、n和Q如权利要求1中定义，通过在碱存在下，将公式II的化合物环化得到，其中R为C(X)OR2或C(X)SR2，其中X为氧或硫，R2如权利要求1中定义。该发明还涉及公式I的化合物，其中如果Z是可选地由Ra取代的亚甲基基团，则W为硫，此外还涉及公式I的化合物，其中Q为苯并噁唑或苯并噻唑基团，并将这些化合物用作除草剂。
• [EN] METHOD FOR THE SYNTHESIS OF DHA<br/>[FR] PROCÉDÉ DE SYNTHÈSE DE DHA
  申请人：PHENOMENOME DISCOVERIES INC

  公开号：WO2012126088A1

  公开（公告）日：2012-09-27

  A method for preparing docosahexaenoic acid (DHA). The method comprises coupling a compound represented by Formula I with a compound represented by Formula II followed by partial hydrogenation to obtain a compound represented by Formula III. The compound represented by Formula III acts as a DHA precursor and thus can be hydrolysed to obtain DHA. Novel starting materials represented by Formula I and Formula II, and synthetic routes for preparing the same are also provided.

  一种制备二十二碳六烯酸（DHA）的方法。该方法包括将由式I表示的化合物与由式II表示的化合物偶联，然后进行部分氢化以获得由式III表示的化合物。由式III表示的化合物作为DHA前体，因此可以水解得到DHA。还提供了由式I和式II表示的新型起始物质，以及用于制备它们的合成路线。
• [EN] 4-(4-PYRIDINYL)-BENZAMIDES AND THEIR USE AS ROCK ACTIVITY MODULATORS<br/>[FR] COMPOSÉS 4-(4-PYRIMIDYL)-BENZAMIDES ET UTILISATION DE CEUX-CI COMME MODULATEURS DE L'ACTIVITÉ DE KINASES RHO (ROCK)
  申请人：ABBOTT GMBH & CO KG

  公开号：WO2009027392A1

  公开（公告）日：2009-03-05

  The present invention relates to novel 4-(4-pyridyl)-benzamides of the formula (I). The compounds I possess valuable therapeutic properties and are suitable, in particular, for treating diseases that respond to modulation of Rho kinases (ROCKs). R1 and R2 are, independently of each other, hydrogen, hydroxy, cyano, C1-C8-alkyl, C1- C8-haloalkyl, C1-C8-alkoxy or C1-C8-haloalkoxy; R3, R4, R5 and R6 are, independently of each other, hydrogen, hydroxy, halogen, cyano, C1-C8-alkyl, C1-C8-haloalkyl, C1-C8-alkoxy, C1-C8-haloalkoxy, amino, C1-C8-alkylamino or di-(C1-C8-alkyl)-amino; R7 is hydrogen, C1-C8-alkyl, C1-C8-haloalkyl, aryl or aryl-C1-C8-alkyl; R8 is a group of the formula -X-W, where X is a single bond, C1-C4-alkylene or C1-C4-alkylene-O-, where the alkylene group in the three last-mentioned radicals may be linear or branched and may be partly or fully halogenated and/or may be substituted by a hydroxyl group and/or may be interrupted by an oxygen atom; and W is a cyclic radical selected from phenyl and a 5- or 6-membered saturated, partly unsaturated or aromatic heterocyclic ring which contains as ring members 1, 2 or 3 heteroatoms selected from O, S and N and optionally 1 or 2 carbonyl groups; R9 is a group of the formula -Y-Z, where Z is hydrogen, halogen, OR11, NR12R13, S(O)m-R14, phenyl which may carry 1, 2, 3 or 4 substituents R15 or a 5- or 6-membered saturated, partly unsaturated or aromatic heterocyclic ring; and Y is linear or branched C1C4-alkylene which may be partly or fully halogenated and/or may be substituted by a hydroxyl group and/or a phenyl ring; or, in case Z is phenyl or the 5- or 6-membered heterocyclic ring as defined above, Y can also be a single bond.

  本发明涉及公式（I）的新型4-(4-吡啶基)-苯甲酰胺。化合物I具有有价值的治疗性能，并且特别适用于治疗对Rho激酶（ROCKs）调节产生反应的疾病。R1和R2分别为氢、羟基、氰基、C1-C8-烷基、C1-C8-卤代烷基、C1-C8-烷氧基或C1-C8-卤代烷氧基；R3、R4、R5和R6分别为氢、羟基、卤素、氰基、C1-C8-烷基、C1-C8-卤代烷基、C1-C8-烷氧基、C1-C8-卤代烷氧基、氨基、C1-C8-烷基氨基或二(C1-C8-烷基)-氨基；R7为氢、C1-C8-烷基、C1-C8-卤代烷基、芳基或芳基-C1-C8-烷基；R8为-X-W的基团，其中X为单键、C1-C4-烷基或C1-C4-烷基-O-，在上述最后三个基团中的烷基可以是直链或支链，可以部分或完全卤代，和/或可以被羟基取代，和/或可以被氧原子打断；W为选择自苯基和含有1、2或3个来自O、S和N的杂原子以及可选地包含1或2个羰基的5-或6-成员饱和、部分不饱和或芳香杂环的环基；R9为-Y-Z的基团，其中Z为氢、卤素、OR11、NR12R13、S(O)m-R14、可能携带1、2、3或4个取代基R15的苯基或5-或6-成员饱和、部分不饱和或芳香杂环的环基；Y为线性或支链的C1-C4-烷基，可以部分或完全卤代，和/或可以被羟基取代，和/或可以是苯环；或者，如果Z为苯基或上述定义的5-或6-成员杂环环，Y也可以是单键。